Why Ghana walked away from a US health deal

ACCRA – Ghana has reportedly put on hold a significant multi-million dollar health deal with the United States, citing profound concerns over the sharing of sensitive health data, particularly patient genomic information. This development, which has seen Accra walk away from an agreement initiated under the Trump administration, highlights a growing trend among African nations to scrutinise the terms of international partnerships, especially those involving critical national assets like health data. The proposed deal, part of a broader US initiative across Africa, aimed to bolster healthcare infrastructure and capabilities. However, Ghanaian officials expressed apprehension that clauses within the agreement could potentially grant the US access to highly sensitive genomic data of Ghanaian citizens without adequate safeguards. This concern is not unique to Ghana; several other African countries have either stalled or rejected similar deals, while some, like Kenya, have proceeded, albeit with varying levels of public and governmental scrutiny. The underlying issue revolves around the potential for exploitation of genetic information and the need for robust data protection frameworks that respect national sovereignty and individual privacy. For Zambia, this development from a fellow African nation offers a crucial lesson in navigating international health partnerships. While foreign aid and investment are vital for strengthening Zambia's public health system, which faces numerous challenges including disease burden and resource constraints, the protection of sensitive patient data must remain paramount. The Zambian government and its health institutions are increasingly engaging with international partners on various health initiatives, from disease surveillance to research and development. Ensuring that such collaborations adhere to stringent data privacy laws, both local and international, is essential to prevent potential misuse or exploitation of Zambian citizens